Annamaria H. Zimmermann - Researcher Profile

Publications

3 shown

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Helmut Oettle , Donald Richards , Rajesh Ramanathan +8 more

2005 Annals of Oncology 304 citations

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

2012 The Lancet Oncology 605 citations

Frequent Co-Authors

Helmut Oettle

Donald Richards

Researcher Info

h-index: 3
Publications: 3
Citations: 1,535
Institution: Eli Lilly (United States)

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.

Publications

Frequent Co-Authors

Researcher Info

External Links

Impact Metrics

Academic Output Over Time